The EUbOPEN consortium (Enabling and Unlocking Biology in the OPEN) aims to generate a comprehensive pharmacological drug library and make it accessible to the research community. The EU project of the Innovative Medicines Initiative (IMI2), which is funded for 5 years, is a collaboration of 22 institutions and pharmaceutical companies. At GSH, active ingredients are to be tested in patient-derived assays. Read more ->
Internationale Fellowships to be granted
Within the Innovative Training Network INTERCEPT-MDS, 12 PhD fellowships are available to develop Europe’s first experts in the research field of disease prevention. Click here to access the application portal with application guidelines, full details of the PhD fellowships, projects and eligibility requirements. Read more ->
Dr. Medyouf participates in EU ITN INTERCEPT-MDS
The research focus of the EU-funded INTERCEPT-MDS project is on myeloid blood cancers and the latest methods of single cell technology to develop innovative research tools for the identification of clonally different cells. In addition, the network unites European expertise in epigenetics and chromatin regulation to specifically identify diseased cells. In doing so, the clinical treatment of diseased cells could be improved in the future using methods of interceptive medicine. Read more ->
New EU research consortium with participation of GSH
Langener Science Award for Prof. Dr. Krause for research on the bone marrow microenvironment
Friday, Nov 15, 2019, Prof. Dr. Daniela Krause received the Langener Science Award at the Paul-Ehrlich-Institute for her work on Home is where the bone is – The bone marrow as an innovative therapeutic approach to blood formation. “We are pleased to honour Prof. Daniela Krause, a scientist who is researching innovative therapeutic approaches and is instrumental in preparing for their rapid testing in clinical trials,” added Prof. Klaus Cichutek, President of PEI. Read more ->